CNTG News and Press, Centogene N.V. From 04/15/21

Centogene N.V. (CNTG) Q4 2020 Earnings Conference Call April 15, 2021 8:00 A.M. ET Company Participants Lennart Streibel - Investor Relations Andrin Oswald - Chief Executive Officer Richard Stoffelen - Chief Financial Officer Conference Call Participants Erin Wright - Credit Suisse Alex Cogut...

The following slide deck was published by Centogene N.V. in conjunction with their 2020 Q4 earnings call. For further details see: Centogene N.V. 2020 Q4 - Results - Earnings Call Presentation

Centogene (CNTG): FY Revenue of €128.4M (+163.2% Y/Y) beats by €84.69M.Press Release For further details see: Centogene beats on revenue

Centogene (CNTG) has extended its partnership with Takeda Pharmaceutical (TAK) to diagnose patients with certain genetic disorders. As part of the agreement, which has been extended until March 2022, Centogene will continue providing access to genetic testing to patients around the world. In ...

CAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, April 14, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical ...

Gainers: [[PFMT]] +13.7%. [[MVIS]] +4.3%. [[CLSD]] +4.2%. [[FLXN]] +3.7%. [[FOLD]] +3.7%.Losers: [[STSA]] -9.9%. [[CNTG]] -7.9%. [[XELB]] -6.2%. [[CLAR]] -5.9%. [[DISCK]] -5.2%. For further details see: PFMT, MVIS, STSA and XELB among after-hours movers

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, April 08, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceuti...

Centogene N.V. (CNTG) announced today that the company has reached a significant milestone in its Rostock International Parkinson's Disease ("ROPAD") study with the recruitment and genetic testing of 10,000 participants.Involving over 120 study sites across the globe, the global obs...

Rostock International Parkinson's Disease (ROPAD) Study aims to characterize the genetics of PD to establish a better understanding of the disease progression, diagnosis, and treatment Significant milestone of 10,000 participants reached With over 120 study sites aroun...

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actiona...